Skip to main content

Table 4 Geometric mean titers and fold increase in pneumococcal immunoglobulin and opsonophagocytic antibodies after PCV-13 vaccination

From: Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy

Baricitinib (N = 106)

Baseline

Week 5

Week 12

Immunoglobulin (μg/mL)

 Serotype 4

Geometric mean (95% CI)

0.48 (0.41, 0.56)

1.39 (1.05, 1.83)

1.20 (0.91, 1.59)

Fold increase (95% CI)

2.8 (2.2, 3.6)*

2.6 (2.0, 3.2)*

 Serotype 6B

Geometric mean (95% CI)

0.89 (0.72, 1.12)

3.32 (2.37, 4.63)

3.10 (2.22, 4.35)

Fold increase (95% CI)

3.6 (2.8, 4.5)*

3.2 (2.6, 4.0)*

 Serotype 14

Geometric mean (95% CI)

1.71 (1.30, 2.25)

4.19 (3.12, 5.64)

4.66 (3.45, 6.28)

Fold increase (95% CI)

2.5 (2.0, 3.2)*

2.5 (1.9, 3.2)*

 Serotype 23F

Geometric mean (95% CI)

0.80 (0.65, 0.99)

2.89 (2.02, 4.14)

2.86 (2.02, 4.05)

Fold increase (95% CI)

3.5 (2.7, 4.5)*

3.4 (2.7, 4.4)*

OI

 Serotype 4

Geometric mean (95% CI)

92.1 (64.8131.0)

1717.9 (1166.0, 2531.1)

1016.8 (688.7, 1501.1)

Fold increase (95% CI)

18.2 (11.8, 28.0)*

11.4 (7.5, 17.2)*

 Serotype 6B

Geometric mean (95% CI)

153.8 (103.1, 229.4)

2153.0 (1431.3, 3238.7)

1519.0 (1029.2, 2241.9)

Fold increase (95% CI)

13.2 (8.5, 20.4)*

9.0 (6.0, 13.4)*

 Serotype 14

Geometric mean (95% CI)

270.2 (176.8, 413.1)

1328.2 (934.2, 1888.3)

1152.0 (811.6, 1635.2)

Fold increase (95% CI)

4.9 (3.2, 7.5)*

3.8 (2.5, 5.7)*

 Serotype 23F

Geometric mean (95% CI)

50.1 (35.1, 71.5)

627.2 (390.5, 1007.3)

489.3 (314.9, 760.3)

Fold increase (95% CI)

12.1 (8.0, 18.5)*

9.3 (6.3, 13.8)*

  1. *p ≤ 0.001 compared to baseline
  2. CI confidence interval, OI opsonization index